Connect your AI

Evommune EVMN Weighted Average Number Of Diluted Share Outstanding

Weighted Average Number Of Diluted Share Outstanding at other companies

Relay Therapeutics, Inc.RLAY

179.8M+6.3%

The BancorpTBBK

42.6M-11.2%

PopularBPOP

64.8M-6.4%

QuidelOrtho CorporationQDEL

68.5M+0.9%

Devon EnergyDVN

2M0.0%

BeldenBDC

38.8M-3.4%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:WeightedAverageNumberOfDilutedShareOutstanding.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's weighted average number of diluted share outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's weighted average number of diluted share outstanding?: Evommune (EVMN) reported weighted average number of diluted share outstanding of 85.1M in Q4 2025.
What does weighted average number of diluted share outstanding mean?: Calculates the average number of shares outstanding during the period, adjusted for the potential conversion of all dilutive securities like options, warrants, and convertible preferred stock. This is the standard denominator used to calculate diluted earnings per share. It provides the most comprehensive view of the company's total potential equity base.